相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Activity of nacubactam (RG6080/OP0595) combinations against MBL-producing Enterobacteriaceae
Shazad Mushtaq et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
In Vivo Efficacy of Meropenem with a Novel Non-β-Lactam-β-Lactamase Inhibitor, Nacubactam, against Gram-Negative Organisms Exhibiting Various Resistance Mechanisms in a Murine Complicated Urinary Tract Infection Model
Marguerite L. Monogue et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment
Paolo Gaibani et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis
Evelina Tacconelli et al.
LANCET INFECTIOUS DISEASES (2018)
Past and Present Perspectives on β-Lactamases
Karen Bush
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in blaKPC-2-Harboring Klebsiella pneumoniae Sequence Type 307 Isolates
Marla J. Giddins et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
In vitro and in vivo activities of the diazabicyclooctane OP0595 against AmpC-derepressed Pseudomonas aeruginosa
Akihiro Morinaka et al.
JOURNAL OF ANTIBIOTICS (2017)
Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate
Anna Both et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Klebsiella pneumoniae Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering
Melissa D. Barnes et al.
MBIO (2017)
ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii
Thomas F. Durand-Reville et al.
NATURE MICROBIOLOGY (2017)
Structural Insights into the TLA-3 Extended-Spectrum β-Lactamase and Its Inhibition by Avibactarn and OP0595
Wanchun Jin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity
Kirk Nelson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Efficacy and Pharmacokinetics of the Combination of OP0595 and Cefepime in a Mouse Model of Pneumonia Caused by Extended-Spectrum-Beta-Lactamase-Producing Klebsiella pneumoniae
Norihito Kaku et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent β-Lactam Enhancer Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Gram-Negative Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group
Yohei Doi et al.
CLINICAL INFECTIOUS DISEASES (2017)
In Vitro and In Vivo Activities of OP0595, a New Diazabicyclooctane, against CTX-M-15-Positive Escherichia coli and KPC-Positive Klebsiella pneumoniae
Akihiro Morinaka et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections
Ryan K. Shields et al.
CLINICAL INFECTIOUS DISEASES (2016)
First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate
Romney M. Humphries et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Variants of β-Lactamase KPC-2 That Are Resistant to Inhibition by Avibactam
Krisztina M. Papp-Wallace et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Activity of Meropenem Combined with RPX7009, a Novel beta-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City
Amabel Lapuebla et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Activity of OP0595/β-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactamases
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam 'enhancer'
Akihiro Morinaka et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Inhibition of Klebsiella β-Lactamases (SHV-1 and KPC-2) by Avibactam: A Structural Study
Nikhil P. Krishnan et al.
PLOS ONE (2015)
Surveillance of Carbapenem-Resistant Klebsiella pneumoniae: Tracking Molecular Epidemiology and Outcomes through a Regional Network
David van Duin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Reclaiming the Efficacy of β-Lactam-β-Lactamase Inhibitor Combinations: Avibactam Restores the Susceptibility of CMY-2-Producing Escherichia coli to Ceftazidime
Krisztina M. Papp-Wallace et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Structural Insight into Potent Broad-Spectrum Inhibition with Reversible Recyclization Mechanism: Avibactam in Complex with CTX-M-15 and Pseudomonas aeruginosa AmpC β-Lactamases
Sushmita D. Lahiri et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases
David E. Ehmann et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Design and Exploration of Novel Boronic Acid Inhibitors Reveals Important Interactions with a Clavulanic Acid-Resistant Sulfhydryl-Variable (SHV) β-Lactamase
Marisa L. Winkler et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases
L. Silvia Munoz-Price et al.
LANCET INFECTIOUS DISEASES (2013)
Understanding the Molecular Determinants of Substrate and Inhibitor Specificities in the Carbapenemase KPC-2: Exploring the Roles of Arg220 and Glu276
Krisztina M. Papp-Wallace et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Importance of Combination Therapy
Mario Tumbarello et al.
CLINICAL INFECTIOUS DISEASES (2012)
Exploring the Role of a Conserved Class A Residue in the Ω-Loop of KPC-2 β-Lactamase A MECHANISM FOR CEFTAZIDIME HYDROLYSIS
Peter S. Levitt et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections
Elizabeth A. Neuner et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2011)
Three Decades of beta-Lactamase Inhibitors
Sarah M. Drawz et al.
CLINICAL MICROBIOLOGY REVIEWS (2010)
Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination
Federico Perez et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Attributable Mortality Rate for Carbapenem-Resistant Klebsiella pneumoniae Bacteremia
Abraham Borer et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2009)
The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria
Patrice Nordmann et al.
LANCET INFECTIOUS DISEASES (2009)
Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Infection and the Impact of Antimicrobial and Adjunctive Therapies
Gopi Patel et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2008)
Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing beta-lactamase KPC-2
H Yigit et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
分享论文
